Pfizer Inc banner

Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 27 USD 1.24% Market Closed
Market Cap: $153.6B

P/B

1.8
Current
4%
More Expensive
vs 3-y average of 1.7

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
1.8
=
Market Cap
$153.8B
/
Total Equity
$86.5B

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
1.8
=
Market Cap
$153.8B
/
Total Equity
$86.5B

Valuation Scenarios

Pfizer Inc is trading above its 3-year average

If P/B returns to its 3-Year Average (1.7), the stock would be worth $25.91 (4% downside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-4%
Maximum Upside
+112%
Average Upside
39%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 1.8 $27
0%
3-Year Average 1.7 $25.91
-4%
5-Year Average 1.9 $28.71
+6%
Industry Average 3.8 $57.32
+112%
Country Average 2.5 $38.23
+42%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close

Market Distribution

In line with most companies in the United States of America
Percentile
38th
Based on 10 946 companies
38th percentile
1.8
Low
0 — 1.5
Typical Range
1.5 — 4.8
High
4.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 1.5
Median 2.5
70th Percentile 4.8
Max 147 580.5

Pfizer Inc
Glance View

Pfizer Inc., a name synonymous with pharmaceutical innovation, embarked on its journey in 1849 when German immigrants Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York. Over the decades, the modest chemical business transformed into a titan of the pharmaceutical industry, delivering breakthroughs that have shaped modern medicine. The company operates through its robust engine of research and development, continually investing billions into discovering and bringing to market medications that address unmet medical needs. Spanning therapeutic areas such as oncology, vaccines, rare diseases, and cardiovascular and metabolic health, Pfizer's strategic focus ensures a diverse product pipeline that aligns with global health trends and challenges. The company's revenue model is predominantly driven by the development, marketing, and sale of its pharmaceutical products. Blockbuster drugs like Lipitor and recently, the COVID-19 vaccine developed in collaboration with BioNTech, have contributed significantly to its earnings. Pfizer's ability to maintain a strong balance between branded pharmaceuticals and generics allows it to effectively cater to both emerging markets and developed economies, while its strategic partnerships and acquisitions further bolster its reach and capabilities. The synergy of science and business acumen at Pfizer has made it not only a hub of medical innovation but also a formidable enterprise in the competitive landscape of healthcare.

PFE Intrinsic Value
31.36 USD
Undervaluation 14%
Intrinsic Value
Price $27
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett